These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35725696)

  • 1. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.
    Ueberroth BE; Jones JC; Bekaii-Saab TS
    Pancreatology; 2022 Sep; 22(6):741-748. PubMed ID: 35725696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.
    Ueberroth BE; Jones JC; Bekaii-Saab T
    Clin Adv Hematol Oncol; 2022 Jul; 20(7):444-455. PubMed ID: 35802877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
    Hata T; Mizuma M; Motoi F; Ohtsuka H; Nakagawa K; Morikawa T; Unno M
    J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):815-824. PubMed ID: 36408698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE
    Clin Cancer Res; 2024 Jul; 30(14):2964-2973. PubMed ID: 38695832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
    Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
    Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
    Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
    Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
    Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
    BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
    Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
    Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.
    Yamaguchi T; Uemura K; Murakami Y; Kondo N; Nakagawa N; Okada K; Seo S; Hiyama E; Takahashi S; Sueda T
    Ann Surg Oncol; 2021 Jun; 28(6):3135-3144. PubMed ID: 33128119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
    Moding EJ; Nabet BY; Alizadeh AA; Diehn M
    Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
    Bent A; Raghavan S; Dasari A; Kopetz S
    Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.